Role of digitalis-like substance in the hypertension of streptozotocin- induced diabetes and simulated weightlessness in rats

Clinical and Experimental Hypertension

Volumn 20, Issue 5-6, 1998, Pages 509-521

  Pamnani, M B ^a   Chen, S ^a   Haddy, F J ^a   Yuan, C ^a   Mo, Z ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Diabetes mellitus; Endogenous digitalis like substance; Hypertension; Rats; Reduced renal mass; Simulated weightlessness; Streptozotocin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; DIGITALIS LIKE FACTOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR FLUID; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RADIOIMMUNOASSAY; RAT; SPACE FLIGHT; STREPTOZOCIN DIABETES; WEIGHTLESSNESS;

EID: 0031873555     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969809053229     Document Type: Conference Paper

References (49)

1. Epstein E, Sowers JR: Diabetes mellitus and hypertension. Hypertension 1992; 19:403-418.
2. Kloewski AS, Canessa M, Warren JH, Laffel LMP, Christleib AR, Knowler RC, Rand LT: Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. New Eng J Med 1988;318:140-145.
3. Cabonell LF, Salom MG, Garcia-Estan J, Salazar FJ, Ubeda M, Quesada T: Hemodynamic alteration in chronically conscious unrestrained diabetic rats. Am J Physiol 1987;252:H900-905.
4. Jackson CV, Carrier GO: Influence of short-term experimental diabetes on blood pressure and heart rate in response to norepinephrine and angiotensin II in the conscious rat. J Cardiovascular Pharmacology. 1983;5:260-265.
5. Kohler L, Biollat N, Luthi P, Atkinson J, Peters-Haefeli L: Influence of streptozotocin-induced diabetes on blood pressure and on renin formation and release. Arch Pharmacol 1980;313:257-261.
6. Kusaka M, Kishi K, Sokabe H: Does so-called streptozotocin hypertension exist in rats Hypertension 1987;10:517-521.
7. O'Donnell MP, Kasiske BL, Keane WF: Glomerular hemodynamics and structural alterations in experimental diabetes mellitus. FASEB J 1988;2:2299-2347.
8. Chen S, Yuan C, Schooley JF, Haddy FJ, Pamnani MB: A consistent model of insulin dependent diabetes mellitus hypertension. Am J Hypertension (in press)
9. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-415.
10. Anderson S, Brenner BM: Role of intraglomerular hypertension in the initiation and progression of renal disease, IN: The kidney in hypertension, ed by NB Kaplan, BM Brenner, JH Laragh, Raven Press, New York, pp 67-75, 1987.
11. + pump concentration in skeletal muscles, heart ventricular muscle and peripheral nerves of rat. Diabetes 1987;36:842-846.
12. +ATPase activity in diabetic heart. Am J Physiol 1983;245:C241-247.
13. +ATPase activity. J Clin Invest 1986;77:503-513.
14. Greene DA, Lattimer SA, Sima AA: Sorbitol, phosphoinositides and sodium potassium ATPase in the pathogenesis of diabetic complications. New Eng J Med 1987;316:599-609.
15. Feldt-Rasmussen B, Mathiesen ER, Deckert T, Giese J, Christensen NJ, Bent-Hansen L, Nielson MD: Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:610-617.
16. Allen TJ, Cooper ME, Obrien RC, Bach LA, Jackson B, Terums G: Glomerular filtration rate in streptozotocin-induced diabetic rats: Role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 1990;39:1182-1190.
17. Haddy FJ, Overbeck HW: The role of humoral agents in volume expanded hypertension. Life Science 1976;19:934-948.
18. + pump in some models of experimental hypertension. Hypertension 1981;(Supple II) 3:II96-III01.
19. + pump and a ouabain-like humoral agent in the genesis of reduced renal mass hypertension. Am J Nephrol 1983;3:92-99.
20. + pump activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertension 1989;2:524-531.
21. Hamlyn JM. Increased levels of a humoral digitalis-like factor in deoxycorticosterone acetate-induced hypertension in the pig. J Endocrin 1989;122:409-420.
22. Blaustein M, Hamlyn J: Sodium transport inhibition, cell calcium, and hypertension: the natriuretic hormone/Na-Ca exchange/hypertension hypothesis. Am J Med 1984;77(4A):45-49.
23. +)-ATPase associated with essential hypertension. Nature 300:1-3, 1982.
24. Nakagawa H, Simanto K, Nakayowa M, Simura O: The role of endogenous digitalis-like factor in hypertensive mechanism in reduced renal mass hypertensive rats. Nippon Naibunpi Gakkai Zasshi 69:462-574, 1993.
25. Leemen FJ, Harmsen E, Yu H, Yuan B: Dietary sodium stimulates ouabain like activity in adrenalelctomized spontaneously hypertensive rats. Am J Physiol 265:H421-424, 1993.
26. Nakagawa H, Simanto K, Nakayowa M, Simura O: The role of endogenous digitalis-like factor in hypertensive mechanism in reduced renal mass hypertensive rats. Nippon Naibunpi Gakkai Zasshi 69:462-574, 1993.
27. Hamlyn JM, Blaustein MP, Bova S, duCharme DW, Harris DW, Mandel F, Matthews WR, Ludens JH: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci Usa 88:6259-6263, 1991.
28. Pamnani MB, W Whitehorn, D Clough, and FJ Haddy: Effects of canrenone in rats with reduced renal mass saline hypertension. Am J Hypertension 3: 188-195, 1993.
29. Johnson PC. The erythropoietic effects of weightlessness. Chapter 12, In: Current concepts in Erythropoiesis, Dunn CDR (Ed.), 1983.
30. Johnson PC, Driscoll TB, LeBlanc AD. Blood volume changes, In: Johnston RS & Dietlein LF (Eds.), Biomedical Results from Skylab, NASA, Washington, DC, NASA SP-377, pp 235-241, 1977.SPACE INTRODUCTION
31. Leonard JI. Understanding metabolic alterations in space flight using quantitative models: Fluid and energy balance. Preprint LAF/IAA-85-325, 36th Congress. Int astro fed, Stockholm, 7-12 Oct, Oxford, Pergammon Press, 1985.
32. Leach CS, Rambaut PC. Biochemical Responses of the Skylab Crewmen: An Overview, In: Johnson RS, & Deitlein LF (Eds.) Biomedical Results from Skylab, NASA, Washington, DC, NASA SP-377 pp 204-216.
33. Sangella GA, AC Shore, ND Markandu, and GA MacGregor. Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet 2:1208-1211, 1985.
34. Yamaji T, M Ishibashi, and F Takaku. Atrial natriuretic factor in human blood. J Clin Invest 76: 1705-1709, 1985.
35. Gonick HC, HJ Kramer, W Paul, and E Lu. Circulating inhibitor of sodium-potassium activated adenosine triphosphatase after expansion of extracellular fluid volume in rats. Clin Sci Mol Med 53:329-334, 1977.
36. Gonick HC, and LF Saldanha. A natriuretic principle derived from kidney tissue of volume-expanded rats. J Clin Invest 56:247-255, 1975.
37. Morey ER. Spaceflight and bone turnover: Correlation with a new rat model of weightlessness. BioScience 29:168-172, 1979.
38. Clough DL, Pamnani MB, Haddy FJ: Decrease myocardial Na-K-ATPase activity in one-kidney, one-clip hypertensive rats. Am J Physiol 1983;245:H244-251.
39. Clough DL: Greater sensitivity to vanadate of rat renal relative to cardiac Na-K-ATPase Life Sciences 1984;35:1937-1946.
40. Chen S, C Yuan, D Clough, J Schooley, FJ Haddy, MB Pamnani. Role of digitalis-like substance in the hypertension of streptozotocin-induced diabetes in reduced renal mass. Hypertens 6:397-406, 1993.
41. Valdes R Jr. Endogenous digoxin-immunoactive factor in human subjects. Fed Proc,1985 44:2800-2805. 1985.
42. Masugi F, Ogihara T, Hasegawa T, Kumahara Y: Ouabain-like and non-ouabain-like factors in plasma of patients with essential hypertension. Clin and Exper theory and practice; 1987:A9(7), 1233-1242.
43. Sealey JE, Laragh JH: Radioimmunoassay of plasma renin activity. Semin Nucle Med 1975;5:189-202.
44. Feilding BA, Price DA, Houlton CA: Enzyme immunoassay for urinary albumin. Clin Chem 1983;29:355-357.
45. Morey ER and DJ Baylink. Inhibition on bone formation during spaceflight. Science 201:1138-1141, 1978.
46. Kimzye SL. Hematology and immunology studies. In: Biomedical Results from Skylab. Johnston RS, LF Deitlin (Eds) NASA SP-377, NASA Washington DC, pp 249-282, 1977.
47. Loy A, Lurie KG, Ghosh A, Wilson JM, Macgregor LC, Matschinsky FM: Diabetes and myo-inositol paradox. Diabetes 1990;39:1305-1312.
48. Pugliese G, Tilton RG, Speedy A, Santarell E, Eades DM, Province MA, Kilo C, Sherman WR, Williamson JR: Modulation of hemodynamic and vascular filtration changes in diabetic rats. Diabetes 1990;39:312-322.
49. Gilmore JP, Zucker ILH. Contribution of vagal pathways to the renal response to head-out immersion in the non human primate. Cir Res 42;263-487,1978.